<DOC>
	<DOC>NCT01022424</DOC>
	<brief_summary>ADPKD patients who were enrolled in Study 156-05-002 will receive repeated oral administration of OPC-41061 at doses of 15 mg twice daily (morning and evening). Administration will be continued until the time of manufacturing and distribution approval of OPC-41061 for ADPKD in Japan.</brief_summary>
	<brief_title>A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients who completed 3year repeated administrations and the followup observation or those who were withdrawn from the study due to reasons other than occurrence of adverse events (based on the judgment of either the subject or the investigator/subinvestigator) in the preceding study (15605002) Patients in whom adverse events occurring in study 15605002 were resolved or became stable and do not require further followup. Patients with eGFR of less than 15 mL/min/1.73 m2 Patients with any of the following complications: Uncontrolled hypertension Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis) Patients with any of the following complications or history thereof: Clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity Inability to personally give consent due to a mental illness</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>Tolvaptan</keyword>
	<keyword>OPC-41061</keyword>
</DOC>